Genelink Return on Equity

Genelink (GNLKQ) currently reports a ROE of 69.53%. That is above the Healthcare sector average of 20.77%. Use the charts on this page to explore Genelink's ROE history and peer comparisons.

Genelink's ROE of 69.53% is higher than the Healthcare sector average of 20.77%. That is roughly 234.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Genelink's current 69.53% should be judged against Healthcare norms (sector average: 20.77%) and against GNLKQ's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 69.53%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Genelink, and consider following GNLKQ for alerts when major investors trade the stock.

Genelink is classified in the Healthcare sector. On ROE, it currently shows 69.53% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GNLKQ with unrelated industries.